Home・Akcijų sąrašas・Fate Therapeutics Inc

Fate Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.43 -3.57

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.4

Max

2.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.2M -31M
Pardavimai	-70K 1.3M
Pelnas, tenkantis vienai akcijai	-0.26
Pelno marža	-2,402.848
Darbuotojai	161
EBITDA	14M -28M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+107.94% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	71M 324M
Ankstesnė atidarymo kaina	6
Ankstesnė uždarymo kaina	2.43

Naujienos nuotaikos

By Acuity

50%

163 / 340 reitingas Healthcare

Fate Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-24 19:07; UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

2026-07-23 21:11; UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

2026-07-22 23:46; UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

2026-07-20 18:26; UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Akcijų palyginimas

Kainos pokytis

Fate Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

107.94% į viršų

12 mėnesių prognozė

Vidutinis 5.24 USD 107.94%

Aukščiausias 8 USD

Žemiausias 2.2 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fate Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Fate Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

163 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.